Asthma management: Important issues

European Respiratory Review

Volumn 14, Issue 97, 2005, Pages 147-151

  Barnes, P ^a   Virchow, J C ^b   Sanchis, J ^d   Welte, T ^c   Pedersen, S ^e  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^e KOLDING HOSPITAL   (Denmark)

Author keywords

Asthma; Dry powder inhaler; Metered dose inhaler; Spacer

Indexed keywords

ANTIINFLAMMATORY AGENT; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BUDESONIDE; CHEMOKINE RECEPTOR CCR3; CORTICOSTEROID; IMMUNOGLOBULIN E ANTIBODY; PHOSPHODIESTERASE IV INHIBITOR; TECHNETIUM 99M; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ASTHMA; DISEASE SEVERITY; FEEDBACK SYSTEM; HUMAN; MEDICAL PRACTICE; MEDICAL SOCIETY; METERED DOSE INHALER; POWDER INHALER; REVIEW; SYMPTOMATOLOGY; UNSPECIFIED SIDE EFFECT;

EID: 33747604364     PISSN: 09059180     EISSN: None     Source Type: Journal    
DOI: 10.1183/09059180.05.00009704     Document Type: Review

References (29)

1. Rabe K, Vermeire P, Soriano J, Maier W. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur Respir J 2000; 16: 802-807.
2. Gruffydd-Jones K. Measuring pulmonary function in practice. Practitioner 2002; 246: 445-449.
3. Global Initiative for Asthma. Global strategy for asthma management and prevention. NHLI/WHO workshop report. National Institute of Health, National Heart, Lung and Blood Institute. NIH Publication Number 02-3659. Updated October 2004.
4. Chetta A, Gerra G, Foresi A, et al. Personality profiles and breathlessness perception in outpatients with different gradings of asthma. Am J Respir Crit Care Med 1998; 157: 116-122.
5. Barnes PJ. Achieving asthma control. Curr Med Res Opin 2005; 21: Suppl. 4, S5-S9.
6. Tiles SA. Differential diagnosis of adult asthma. Med Clin North Am 2006; 90: 61-76.
7. Selroos O, Lofroos AB, Pietinalho A, Riska H. Asthma control and steroid doses 5 years after early or delayed introduction of inhaled corticosteroids in asthma: a real-life study. Respir Med 2004; 98: 254-262.
8. Veen JC, Smits HH, Ravensbert AJ, Hiemstra PS, Sterk PJ, Bel EH. Impaired perception of dyspnea in patients with severe asthma. Relation to sputum eosinophils. Am J Respir Crit Care Med 1998; 158: 1134-1141.
9. Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved: The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004; 170: 836-844.
10. O'Byrne PM, Bisgaard H, Godard PP, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005; 171: 129-136.
11. Paulwels RA, Lofdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997; 337: 1405-1411.
12. Sont JK, Willems LN, Bel EH, van Krieken JH, Vandenbroucke JP, Sterk PJ. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group. Am J Respir Crit Care Med 1999; 159: 1043-1051.
13. Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002; 360: 1715-1721.
14. Smith AD, Cowan JO, Brassett KP, Herbison GP, Taylor DR. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med 2005; 352: 2163-2173.
15. D'Souza W, Burgess C, Ayson M, Crane J, Pearce N, Beasley R. Trial of a "credit card" asthma self-management plan in a high-risk group of patients with asthma. J Allergy Clin Immunol 1996; 97: 1085-1092.
16. Newman S, Pitcairn G, Hirst P, et al. Scintigraphic comparison of budesonide deposition from two dry powder inhalers. Eur Respir J 2000; 16: 178-183.
17. Virchow JC. What plays a role in the choice of inhaler device for asthma therapy? Curr Med Res Opin 2005; 21: Suppl. 4, S19-S25.
18. Kohler D. The Novolizer: overcoming inherent problems of other dry powder inhalers. Respir Med 2004; 98: Suppl. A, S17-S21.
19. Rolinck-Werninghaus C, Wahn U, Hamelmann E. Anti-IgE therapy in allergic asthma. Curr Drug Targets Inflamm Allergy 2005; 4: 551-564.
20. Howarth PH, Babu KS, Arshad HS, et al. Tumour necrosis factor (TNF alpha) as a novel therapeutic target in symptomatic corticosteroids dependent asthma. Thorax 2005; 60: 1012-1018.
21. Jonkers RK, van der Zee JS. Anti-IgE and new immunomodulation-based therapies for allergic asthma. Neth J Med 2005; 63: 121-128.
22. Grootendorst DC, Gauw SA, Benschop N, Sterk PJ, Hiemstra PS, Rabe KF. Efficacy of the novel phosphodiesterase-4 inhibitor BAY 19-8004 on lung function and airway inflammation in asthma and chronic obstructive pulmonary disease (COPD). Pulm Pharmacol Ther 2003; 16: 341-347.
23. Pedersen S, Frost L, Arnfred T. Errors in inhalation technique and efficiency in inhaler use in asthmatic children. Allergy 1986; 41: 118-124.
24. Everard ML, Devadason SG, Le Souef PN. Flow early in the inspiratory manoeuvre affects the aerosol particle size distribution from a Turbuhaler. Respir Med 1997; 91: 624-628.
25. Kohler D. Novolizer: new technology for the management of asthma therapy. Curr Opin Pulm Med 2003; 9: Suppl. 1, S11-S16.
26. Von Berg A, Papageorgiou Saxoni F, Wille S, Carrillo T, Kattamis C, Helms PJ. Asthmatic children generate significantly different peak inspiratory flow rates (PIFR) through two different dry powder inhalers (DPIs). Eur Respir J 2003; 53: 562-567.
27. Vogelberg C, Kremer H, Ellers-Lenz B, et al. Clinical evaluation of the peak inspiratory flow generated by asthmatic children through the Novolizer. Respir Med 2004; 98: 924-931.
28. Lenny J, Innes J, Crompton G. Inappropriate inhaler use: assessment of use and patient preference of seven inhalation devices. Respir Med 2000; 94: 496-500.
29. Munzel U, Marschall K, Fyrnys B, Wedel M. Variability of fine particle dose and lung deposition of budesonide delivered through two multiple dose dry powder inhalers. Curr Med Res Opin 2005; 21: 827-833.